David Kelly Biography and Net Worth

Director of Mesa Laboratories

Mr. Kelly currently serves as a member of the Board of Directors of Mestek (OTC: MCCK), and a privately held company, and previously served on the Board of Directors of Federated Investors, Inc. (NYSE: FII). In 1995, Mr. Kelly joined Matthews International Corporation, where he served as Chairman of the Board, Chief Executive Officer and President until his retirement in 2007. From 1972 to 1995, Mr. Kelly was with Carrier Corporation and held a variety of executive positions, in the United States and in Asia, in marketing, finance, manufacturing and operations, including President of North America operations. He received a Bachelor of Science degree in Physics from Boston College in 1964, a Master’s degree in Molecular Biophysics from Yale in 1966, and a Master of Business Administration degree from Harvard Business School in 1968.

What is David M. Kelly's net worth?: The estimated net worth of David M. Kelly is at least $10.58 million as of December 11th, 2023. Mr. Kelly owns 80,097 shares of Mesa Laboratories stock worth more than $10,579,212 as of December 22nd. This net worth estimate does not reflect any other assets that Mr. Kelly may own. Learn More about David M. Kelly's net worth.
How do I contact David M. Kelly?: The corporate mailing address for Mr. Kelly and other Mesa Laboratories executives is 12100 W 6TH AVE, LAKEWOOD CO, 80228. Mesa Laboratories can also be reached via phone at (303) 987-8000 and via email at [email protected]. Learn More on David M. Kelly's contact information.
Has David M. Kelly been buying or selling shares of Mesa Laboratories?: David M. Kelly has not been actively trading shares of Mesa Laboratories during the past quarter. Most recently, David M. Kelly sold 18 shares of the business's stock in a transaction on Monday, November 8th. The shares were sold at an average price of $324.07, for a transaction totalling $5,833.26. Learn More on David M. Kelly's trading history.
Who are Mesa Laboratories' active insiders?: Mesa Laboratories' insider roster includes Brian Archbold (SVP), Gregory DiNoia (SVP), Evan Guillemin (Director), David Kelly (Director), Gary Owens (CEO), John Sakys (CFO), John Schmieder (Director), and John Sullivan (Director). Learn More on Mesa Laboratories' active insiders.
Are insiders buying or selling shares of Mesa Laboratories?: During the last twelve months, insiders at the medical instruments supplier sold shares 2 times. They sold a total of 4,017 shares worth more than $473,470.16. The most recent insider tranaction occured on October, 28th when CEO Gary M Owens sold 2,518 shares worth more than $286,095.16. Insiders at Mesa Laboratories own 4.4% of the company. Learn More about insider trades at Mesa Laboratories.
Information on this page was last updated on 10/28/2024.

David M. Kelly Insider Trading History at Mesa Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/8/2021	Sell	18	$324.07	$5,833.26
8/31/2021	Sell	603	$267.29	$161,175.87
6/4/2021	Sell	851	$260.28	$221,498.28	2,772
12/11/2020	Sell	250	$283.18	$70,795.00	2,350
11/16/2020	Sell	704	$283.31	$199,450.24	3,304
8/31/2020	Sell	600	$245.00	$147,000.00	2,990
8/28/2020	Sell	180	$244.00	$43,920.00	2,990
8/17/2020	Sell	800	$247.72	$198,176.00	3,610
8/10/2020	Sell	1,371	$250.00	$342,750.00	3,154
3/19/2019	Sell	684	$230.00	$157,320.00	3,584
2/6/2019	Sell	2,000	$229.62	$459,240.00	3,900
12/6/2018	Sell	1,700	$210.94	$358,598.00	3,600
9/13/2018	Sell	700	$190.01	$133,007.00	3,600
6/12/2017	Sell	1,000	$142.00	$142,000.00	4,750

David M. Kelly Buying and Selling Activity at Mesa Laboratories

Mesa Laboratories Company Overview

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Today's Range

Now: $132.08

$129.75

$136.27

50 Day Range

MA: $120.47

$98.59

$135.91

2 Week Range

Now: $132.08

$83.68

$141.17

Volume

141,746 shs

Average Volume

41,646 shs

Market Capitalization

$717.19 million

P/E Ratio

N/A

Dividend Yield

0.50%

Beta

0.86

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment

From Behind the Markets | Ad

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>